Yelin Lapidot Holdings Management Ltd. Grows Holdings in MediWound Ltd. (NASDAQ:MDWD)

Yelin Lapidot Holdings Management Ltd. increased its position in MediWound Ltd. (NASDAQ:MDWDFree Report) by 45.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 125,493 shares of the biopharmaceutical company’s stock after acquiring an additional 39,348 shares during the quarter. Yelin Lapidot Holdings Management Ltd.’s holdings in MediWound were worth $1,276,000 at the end of the most recent quarter.

Separately, Silverberg Bernstein Capital Management LLC purchased a new stake in MediWound in the 4th quarter worth approximately $803,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

MediWound Stock Down 3.4 %

MDWD stock traded down $0.57 during midday trading on Friday, hitting $16.39. The company’s stock had a trading volume of 32,695 shares, compared to its average volume of 49,201. MediWound Ltd. has a 12 month low of $7.10 and a 12 month high of $19.86. The firm has a market capitalization of $155.54 million, a price-to-earnings ratio of -21.29 and a beta of 0.81. The company has a 50 day moving average of $16.68 and a two-hundred day moving average of $13.41.

MediWound (NASDAQ:MDWDGet Free Report) last posted its quarterly earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.04. MediWound had a negative return on equity of 20.22% and a negative net margin of 35.94%. The business had revenue of $5.34 million during the quarter, compared to the consensus estimate of $5.33 million. On average, analysts anticipate that MediWound Ltd. will post -1.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on MDWD shares. StockNews.com raised shares of MediWound to a “sell” rating in a report on Wednesday, May 8th. HC Wainwright restated a “buy” rating and issued a $28.00 price target on shares of MediWound in a research note on Friday, March 22nd.

Get Our Latest Research Report on MediWound

MediWound Profile

(Free Report)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

Featured Stories

Want to see what other hedge funds are holding MDWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MediWound Ltd. (NASDAQ:MDWDFree Report).

Institutional Ownership by Quarter for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.